消化器内科学（第１）

Medicine & Life Sciences

1. Stomach Neoplasms 100%
2. Helicobacter pylori 76%
3. Ulcerative Colitis 75%
4. Methylation 65%
5. Stomach 64%
6. Gastric Mucosa 62%
7. Japan 55%
8. Neoplasms 50%
9. CpG Islands 48%
10. Pancreatic Neoplasms 46%
11. Endoscopy 43%
12. DNA Methylation 42%
13. Hepatocellular Carcinoma 41%
14. Narrow Band Imaging 41%
15. MicroRNAs 38%
16. Endoscopic Mucosal Resection 37%
17. Elasticity Imaging Techniques 32%
18. Pancreas 31%
19. Helicobacter Infections 31%
20. Genes 30%
21. Adenocarcinoma 29%
22. Chronic Pancreatitis 29%
23. Gastritis 25%
24. Genotype 25%
25. Non-alcoholic Fatty Liver Disease 25%
26. Colorectal Neoplasms 24%
27. Liver 23%
28. Therapeutics 22%
29. Double-Balloon Enteroscopy 22%
30. Dyspepsia 21%
31. Adenoma 21%
32. Atrophy 21%
33. Confidence Intervals 20%
34. Fine Needle Biopsy 20%
35. Multicenter Studies 20%
36. Survival 19%
37. Drug Therapy 19%
38. Odds Ratio 19%
39. 1-kestose 19%
40. Mucous Membrane 18%
41. Alleles 18%
42. Pancreatic Diseases 18%
43. Biopsy 18%
44. Sclerosing Cholangitis 17%
45. Steroids 17%
46. Chronic Hepatitis C 17%
47. Fibrosis 17%
48. Sorafenib 16%
49. Endosonography 15%
50. Polyps 15%
51. Gastrointestinal Stromal Tumors 15%
52. Genetic Polymorphisms 15%
53. Polypyrimidine Tract-Binding Protein 15%
54. Carcinogenesis 15%
55. Ultrasonography 15%
56. atezolizumab 14%
57. Metaplasia 14%
58. Pylorus 14%
59. Interferons 14%
60. Indigo Carmine 14%
61. Gallbladder 13%
62. Inflammation 13%
63. Recurrence 13%
64. Gastrointestinal Microbiome 13%
65. Pepsinogen A 13%
66. PAR-2 Receptor 13%
67. Hemorrhage 13%
68. Progression-Free Survival 13%
69. Cancer-Associated Fibroblasts 13%
70. Hepacivirus 13%
71. Gallbladder Neoplasms 12%
72. Phenotype 12%
73. Lasers 12%
74. Retrospective Studies 12%
75. Guidelines 12%
76. Marginal Zone B-Cell Lymphoma 11%
77. Autoimmune Pancreatitis 11%
78. Lactoferrin 11%
79. Epigenomics 11%
80. Population 11%
81. Crohn Disease 11%
82. Gastroenterology 11%
83. Toll-Like Receptor 2 11%
84. Ulcer 10%
85. Polymerase Chain Reaction 10%
86. Telomere Shortening 10%
87. Safety 10%
88. Bevacizumab 10%
89. Homozygote 10%
90. Blood Vessels 10%
91. Prospective Studies 10%
92. Hardness 10%
93. Elderly 10%
94. Muscles 9%
95. Small Intestine 9%
96. Phospholipases 9%
97. Portal Vein 9%
98. Aspartate Aminotransferases 9%
99. Sensitivity and Specificity 9%
100. Pyruvate Kinase 9%